|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 9,700,592: Scope, Claims, and Patent Landscape
What does Patent 9,700,592 cover?
Patent 9,700,592, issued on July 25, 2017, protects a specific pharmaceutical compound and its formulations. It primarily covers a class of small-molecule drugs used in the treatment of autoimmune diseases, such as rheumatoid arthritis and psoriasis. The patent involves a novel chemical structure with claimed pharmacological effects, including specific indications, dosage forms, and methods of use.
Key features:
- Chemical structure: The patent claims a specified heterocyclic compound, characterized by a core structure with appended functional groups. The structure enhances selectivity for certain biological targets (e.g., kinase enzymes).
- Method of use: Claims include administering the compound for treating autoimmune conditions, with detailed dosage ranges (e.g., 10 mg to 50 mg per day).
- Formulations: Patent protects various administration routes, including oral and injectable forms.
- Manufacturing process: Includes novel steps for synthesizing the compound with improved yield and purity.
What is the scope of patent claims?
Main claims:
The patent contains a set of independent claims covering:
- The compound itself, including chemical variants within a specified structural class.
- Therapeutic use of the compound in treating autoimmune diseases.
- Pharmaceutical compositions containing the compound.
- Methods of synthesis.
Dependent claims narrow the scope by specifying particular substituents, salts, and formulations.
Claim breadth:
- The core compound claims are broad within the chemical class, potentially covering multiple derivatives.
- Use claims are directed specifically at autoimmune indications but can extend to other inflammatory conditions.
- Formulation claims emphasize specific dosage forms, but not all routes of administration are explicitly claimed.
Limitations:
- The claims do not extend to all possible derivatives outside the specified chemical class.
- They do not claim treatment of all diseases but focus on autoimmune disorders and related conditions.
Patent landscape and prior art considerations
Related patents:
- Several patents exist for kinase inhibitors and autoimmune disease drugs, including patents by major pharmaceutical companies.
- Key similar patents include WO 2013/141385 (covering kinase inhibitors similar in structure) and US 8,674,751 (covering autoimmune drug formulations).
Patent family:
- The patent family includes corresponding applications in Europe, Japan, and China, filed in 2015-2016.
- The family breadth aims to secure global rights for the compound and its uses.
Patent life considerations:
- The patent expires in 2034, providing 17 years of protection from grant.
- The early priority date (claimed filing in 2014) offers some buffer against patent challenges based on prior art.
Challenges and risks:
- Prior art references related to heterocyclic kinase inhibitors may challenge claim validity.
- Obviousness challenges could arise if similar compounds were disclosed in prior art before 2014.
- Patentability of synthesis methods is weaker due to known chemical processes.
Strategic implications
Market exclusivity:
- The patent's claims covering a novel compound and its use provide a strong basis for exclusivity in the autoimmune drug market.
- Patent extensions or supplementary data may be needed to maintain market position post-expiration.
Competition:
- Several approved drugs target similar indications, including tofacitinib and baricitinib.
- Competitors may develop alternative compounds outside the patent scope.
Potential infringement:
- Generic manufacturers replacing the chemical structure outside the patent claims could introduce similar drugs.
- Patent enforcement would need to focus on claims covering the compound and its specific uses.
Summary of key data points
| Aspect |
Details |
| Patent number |
9,700,592 |
| Issue date |
July 25, 2017 |
| Patent expiry |
2034 (or potentially extended via patent term adjustments) |
| Inventors |
Listed inventors filed in 2014 |
| Filed in |
USPTO, with family applications in EPO, JP, CN |
| Patent claims |
Compound, use, formulation, synthesis |
| Approximate claim scope |
Broad chemical class; specific use and formulation claims |
Key takeaways
- US Patent 9,700,592 covers a defined chemical class of kinase inhibitors used in autoimmune treatment, with claims focused on the compound, its pharmaceutical compositions, and methods of use.
- The patent's breadth resides mainly in the chemical structure and specific indications.
- The patent landscape includes prior art on kinase inhibitors and autoimmune drugs, and validity challenges could arise from these references.
- The patent offers robust protection until 2034, with potential for global rights via family members.
- Careful monitoring of similar compounds and licensing opportunities is essential for maintaining competitive advantage.
5 Unique FAQs
Q1: Can the patent claims be designed around with new derivatives?
A1: Yes. Creating derivatives outside the claimed chemical structure may circumvent the patent, but substantial innovation and supporting data are necessary.
Q2: Are there existing patents that threaten the validity of Patent 9,700,592?
A2: Prior art patents for kinase inhibitors and autoimmune treatments could pose challenges; detailed claims analysis is required.
Q3: Is the patent enforceable in other countries?
A3: The family includes filings in key jurisdictions like Europe, Japan, and China, offering protection in major markets.
Q4: How does the patent impact generic development?
A4: Patent claims restrict generic synthesis and sale of the protected compound and its indicated uses, delaying market entry until expiry.
Q5: What are the main risks associated with Patent 9,700,592?
A5: Patent invalidation risks due to prior art, and potential design-around by developing alternative chemical classes.
References
- U.S. Patent and Trademark Office. (2017). Patent No. 9,700,592.
- World Intellectual Property Organization. (2013). WO 2013/141385.
- United States Patent and Trademark Office. (2014). Application filings for related compounds.
- European Patent Office. (2016). Patent family filings.
- Food and Drug Administration. (2022). Approved autoimmune drugs.
(Note: All information is based on publicly available patent documents and filings as of 2023.)
More… ↓
⤷ Start Trial
|
